SCHEMBL6486967

SCHEMBL6486967

Cc1cc(Cc2ccc(C(=O)O)cc2)c(=O)n2c1CC(C#Cc1ccccc1)=N2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.38
FFAR1 O14842 3/20 0.37
CHRM2 P08172 1/20 0.37
S1PR1 P21453 1/20 0.37
FPR1 P21462 1/20 0.37
FPR3 P25089 1/20 0.37
GPR183 P32249 1/20 0.37
APLNR P35414 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
GPR65 Q8IYL9 1/20 0.37
TSHR P16473 1/20 0.37
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
KAT8 Q9H7Z6 1/20 0.35
RARA P10276 2/20 0.35
RARB P10826 2/20 0.35
RARG P13631 2/20 0.35
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
ACACB O00763 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488181 0.77 NR1H4 (0.44) RXRAMMP13LMNA
SCHEMBL6488680 0.73 TSHR (0.38) RXRAFFAR1CHRM2S1PR1FPR1
SCHEMBL6490898 0.72 TSHR (0.37) RXRAFFAR1CHRM2S1PR1FPR1
SCHEMBL6817760 0.70 MAPT (0.38) MMP13LMNAPOLB
SCHEMBL6486746 0.66 NR1H4 (0.45) RXRATSHRMMP13LMNAPOLB
SCHEMBL27986872 0.65 TSHR (0.69) RXRAFFAR1TSHRRXRBRXRG
SCHEMBL6486971 0.63 ALDH1A1 (0.35) RXRARARARARBRARGMEN1
SCHEMBL6476082 0.63 TSHR (0.37) RXRAFFAR1CHRM2S1PR1FPR1
SCHEMBL6487488 0.62 TSHR (0.38) RXRAFFAR1CHRM2S1PR1FPR1
SCHEMBL402518 0.61 RARB (0.62) FFAR1FFAR4TSHRRARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 RXRA 1370/4885FFAR1 1620/4885CHRM2 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.